CO2018013827A2 - Procesos para preparar oligómeros de morfolino fosforodiamidato - Google Patents

Procesos para preparar oligómeros de morfolino fosforodiamidato

Info

Publication number
CO2018013827A2
CO2018013827A2 CONC2018/0013827A CO2018013827A CO2018013827A2 CO 2018013827 A2 CO2018013827 A2 CO 2018013827A2 CO 2018013827 A CO2018013827 A CO 2018013827A CO 2018013827 A2 CO2018013827 A2 CO 2018013827A2
Authority
CO
Colombia
Prior art keywords
processes
oligomer
preparing
morpholino phosphorodiamidate
preparing morpholino
Prior art date
Application number
CONC2018/0013827A
Other languages
English (en)
Inventor
Bao Cai
Mitchell Martini
Ross Shimabuku
Katie Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of CO2018013827A2 publication Critical patent/CO2018013827A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a procesos para preparar un oligómero (por ejemplo, un oligómero de morfolino). Los procesos sintéticos descritos en la presente pueden ser ventajosos para el escalar la síntesis de oligómeros mientras se mantiene el rendimiento general y pureza de un oligómero sintetizado.
CONC2018/0013827A 2016-05-24 2018-12-19 Procesos para preparar oligómeros de morfolino fosforodiamidato CO2018013827A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340953P 2016-05-24 2016-05-24
US201662357134P 2016-06-30 2016-06-30
PCT/US2017/034284 WO2017205513A1 (en) 2016-05-24 2017-05-24 Processes for preparing phosphorodiamidate morpholino oligomers

Publications (1)

Publication Number Publication Date
CO2018013827A2 true CO2018013827A2 (es) 2018-12-28

Family

ID=59078166

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013827A CO2018013827A2 (es) 2016-05-24 2018-12-19 Procesos para preparar oligómeros de morfolino fosforodiamidato

Country Status (19)

Country Link
US (2) US10961262B2 (es)
EP (1) EP3464306B1 (es)
JP (1) JP6987081B2 (es)
KR (1) KR102504759B1 (es)
CN (1) CN109311920B (es)
AU (1) AU2017271524B2 (es)
BR (1) BR112018074270B1 (es)
CA (1) CA3024182A1 (es)
CO (1) CO2018013827A2 (es)
DK (1) DK3464306T3 (es)
FI (1) FI3464306T3 (es)
IL (1) IL263033B2 (es)
LT (1) LT3464306T (es)
MA (1) MA45155A (es)
MX (1) MX2018014162A (es)
SA (1) SA518400462B1 (es)
SG (1) SG11201809499UA (es)
TW (1) TWI737736B (es)
WO (1) WO2017205513A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CN109563114B (zh) * 2016-05-24 2022-08-12 萨勒普塔医疗公司 用于制备寡聚物的方法
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
DK3464306T3 (da) * 2016-05-24 2024-05-21 Sarepta Therapeutics Inc Fremgangsmåder til fremstilling af phosphorodiamidat-morpholino-oligomerer
KR102523527B1 (ko) * 2016-06-30 2023-04-20 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
CA3024153A1 (en) * 2016-06-30 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
WO2019060862A1 (en) * 2017-09-25 2019-03-28 Sarepta Therapeutics, Inc. METHODS FOR PREPARING MORPHOLINO PHOSPHORODIAMIDATE OLIGOMERS VIA FAST FLOW SYNTHESIS
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
WO2021187392A1 (ja) * 2020-03-16 2021-09-23 国立大学法人東京医科歯科大学 モルホリノ核酸を含むヘテロ核酸
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023077120A1 (en) * 2021-11-01 2023-05-04 Dyne Therapeutics, Inc. Muscle targeting complexes for treating dystrophinopathies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE171185T1 (de) 1985-03-15 1998-10-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
DE68914843T2 (de) 1988-09-01 1994-11-10 Risoe Forskningscenter Peptid-synthese und fester träger zur verwendung dabei.
HUT76280A (en) 1993-12-29 1997-07-28 Fujisawa Pharmaceutical Co Pyrazolopyridine derivatives, pharmaceutical compositions containing them, process for proiducing them and their use
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
WO2003020739A2 (en) 2001-09-04 2003-03-13 Exiqon A/S Novel lna compositions and uses thereof
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003291682A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
DK1766010T3 (da) 2004-06-28 2011-06-06 Univ Western Australia Antisense-oligonukleotider til induktion af exon-skipping og fremgangsmåder til anvendelse deraf
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US8299206B2 (en) * 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
CN101861318A (zh) 2007-11-15 2010-10-13 Avi生物制药公司 合成吗啉代低聚物的方法
CN102625840A (zh) 2009-04-10 2012-08-01 肌肉学研究协会 用于治疗疾病的三环dna反义寡核苷酸、组合物和方法
KR102366851B1 (ko) 2009-11-12 2022-02-23 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
TWI463423B (zh) * 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
NZ603606A (en) * 2010-05-28 2015-06-26 Sarepta Therapeutics Inc Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
ES2607603T3 (es) 2010-09-30 2017-04-03 Nippon Shinyaku Co., Ltd. Derivado de ácido morfolino nucleico
WO2012109296A1 (en) * 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Antisense oligonucleotides
WO2013026142A1 (en) 2011-08-23 2013-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University Ionic tags for synthesis of oligoribonucleotides
DK2581448T3 (en) 2011-10-13 2015-04-27 Ass Inst De Myologie Tricyclo-DNA phosphorothioate
KR20140097398A (ko) 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
EP2785840B8 (en) 2011-11-30 2019-05-22 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
IN2014DN06220A (es) * 2011-12-28 2015-10-23 Nippon Shinyaku Co Ltd
WO2013128281A1 (en) 2012-02-28 2013-09-06 Population Genetics Technologies Ltd Method for attaching a counter sequence to a nucleic acid sample
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
LT2970964T (lt) * 2013-03-14 2019-04-25 Sarepta Therapeutics, Inc. Kompozicijos su egzono praleidimu, skirtos raumenų distrofijos gydymui
WO2014153220A2 (en) * 2013-03-14 2014-09-25 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US8999152B2 (en) * 2013-03-15 2015-04-07 Uop Llc Process and apparatus for recovering and blending hydroprocessed hydrocarbons and composition
EP3015467A4 (en) 2013-05-24 2016-11-02 Ajinomoto Kk PROCESS FOR THE PRODUCTION OF MORPHOLINO-OLIGONUCLEOTIDE
DK3464306T3 (da) 2016-05-24 2024-05-21 Sarepta Therapeutics Inc Fremgangsmåder til fremstilling af phosphorodiamidat-morpholino-oligomerer
MA45362A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
CN109563114B (zh) * 2016-05-24 2022-08-12 萨勒普塔医疗公司 用于制备寡聚物的方法
IL263044B1 (en) 2016-05-24 2024-02-01 Sarepta Therapeutics Inc Processes for the preparation of phosphorodiamidate morpholino oligomers
NZ755416A (en) 2016-12-19 2023-05-26 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy

Also Published As

Publication number Publication date
FI3464306T3 (fi) 2024-05-16
TW201825506A (zh) 2018-07-16
WO2017205513A1 (en) 2017-11-30
US20190276480A1 (en) 2019-09-12
BR112018074270B1 (pt) 2021-02-02
SG11201809499UA (en) 2018-12-28
CA3024182A1 (en) 2017-11-30
KR20190013844A (ko) 2019-02-11
JP2019523754A (ja) 2019-08-29
MA45155A (fr) 2019-04-10
SA518400462B1 (ar) 2022-06-12
LT3464306T (lt) 2024-05-10
AU2017271524A1 (en) 2018-11-15
EP3464306A1 (en) 2019-04-10
BR112018074270A2 (pt) 2019-03-12
JP6987081B2 (ja) 2021-12-22
US20220340605A1 (en) 2022-10-27
DK3464306T3 (da) 2024-05-21
IL263033A (en) 2018-12-31
TWI737736B (zh) 2021-09-01
EP3464306B1 (en) 2024-03-27
CN109311920B (zh) 2021-11-09
CN109311920A (zh) 2019-02-05
US10961262B2 (en) 2021-03-30
MX2018014162A (es) 2019-04-01
KR102504759B1 (ko) 2023-02-28
AU2017271524B2 (en) 2021-06-24
IL263033B2 (en) 2023-02-01
IL263033B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
CO2018013827A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013834A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013838A2 (es) Procesos para preparar oligómeros
CO2018013831A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2019002975A2 (es) Compuestos de tetraciclina y métodos de uso de los mismos
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
EA201992183A2 (ru) Синтез полициклических карбамоилпиридоновых соединений
CO2019006018A2 (es) Polimorfos de sepiapterina y sus sales
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
MX2019000664A (es) Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5 ciclopentadecanediona.
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
CY1120763T1 (el) Νεες ενωσεις σουλφονυλαμινοβενζαμιδιου
WO2017112809A8 (en) System and method for solution phase gap peptide synthesis
DOP2016000211A (es) Pirazinas moduladoras de gpr6
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
CU24518B1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
CL2023000942A1 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso .
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.
BR112015028751A2 (pt) processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas
EA201791098A1 (ru) Способ синтеза производных бензазепина